Drug Trial Radar · NCT07284875
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,530
Actual
Start
Dec 18, 2025
Primary completion
Feb 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- KaileraIndustry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Conditions
- Obesity
- Overweight
Interventions
RibupatideDrug
SC Injection
PlaceboDrug
SC Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose 3 and 4 versus Placebo: Percent Change From Baseline in Body Weight at Week 76Time frame: Baseline, Week 76
Locations
110 sites in 10 countries. Site status is shown where the registry gives one.
Kailera Clinical Site
Anniston, Alabama
Kailera Clinical Site
Birmingham, Alabama
Kailera Clinical Site
Cullman, Alabama
Kailera Clinical Site
Sun City, Arizona
Kailera Clinical Site
Escondido, California
Kailera Clinical Site
Toluca Lake, California
Kailera Clinical Site
Aurora, Colorado
Kailera Clinical Site
Bridgeport, Connecticut
Kailera Clinical Site
Jupiter, Florida
Kailera Clinical Site
Lilburn, Georgia
Kailera Clinical Site
Springfield, Illinois
Kailera Clinical Site
Columbia, Maryland
Kailera Clinical Site
Las Vegas, Nevada
Kailera Clinical Site
Rochester, New York
Kailera Clinical Site
Morehead City, North Carolina
Kailera Clinical Site
Chickasha, Oklahoma
Kailera Clinical Site
Mauldin, South Carolina
Kailera Clinical Site
Chattanooga, Tennessee
Kailera Clinical Site
Amarillo, Texas
Kailera Clinical Site
Bellaire, Texas
Kailera Clinical Site
DeSoto, Texas
Kailera Clinical Site
Tomball, Texas
Kailera Clinical Site
Salt Lake City, Utah
Kailera Clinical Site
Danville, Virginia
Kailera Clinical Site
CABA, Argentina
Kailera Clinical Site
Córdoba, Argentina
Kailera Clinical Site
La Plata, Buenos Aires, Argentina
Kailera Clinical Site #1
San Nicolás de los Arroyos, Buenos Aires, Argentina
Kailera Clinical Site #2
San Nicolás de los Arroyos, Buenos Aires, Argentina
Kailera Clinical Site #1
Buenos Aires, Buenos Aires F.D., Argentina
Kailera Clinical Site #2
Buenos Aires, Buenos Aires F.D., Argentina
Kailera Clinical Site
Buenos Aires, Buenos Aires F.D., Argentina
Kailera Clinical Site
Buenos Aires, Buenos Aires F.D., Argentina
Kailera Clinical Site
Godoy Cruz, Mendoza Province, Argentina
Kailera Clinical Site #1
Rosario, Santa Fe Province, Argentina
Kailera Clinical Site #2
Rosario, Santa Fe Province, Argentina
Kailera Clinical Site #3
Rosario, Santa Fe Province, Argentina
Kailera Clinical Site
Charlestown, New South Wales, Australia
Kailera Clinical Site
Sydney, New South Wales, Australia
Kailera Clinical Site
Sydney, New South Wales, Australia
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.